Bibliometric analysis of research trends on the combination of immune checkpoint inhibitors and PARP inhibitors in solid tumors
Introduction: Immune checkpoint inhibitors (ICIs) has made significant achievements in the therapeutics of various tumor types, and recently growing evidence from preclinical studies and clinical trials has indicated that poly-ADP-ribose polymerase inhibitors (PARPi) are exhibiting encouraging syner...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844024004833 |
| _version_ | 1797328682453303296 |
|---|---|
| author | Yaqian Tan Qi Song |
| author_facet | Yaqian Tan Qi Song |
| author_sort | Yaqian Tan |
| collection | DOAJ |
| description | Introduction: Immune checkpoint inhibitors (ICIs) has made significant achievements in the therapeutics of various tumor types, and recently growing evidence from preclinical studies and clinical trials has indicated that poly-ADP-ribose polymerase inhibitors (PARPi) are exhibiting encouraging synergism with ICIs. The aim of our current study is to explore the development pattern of literature related to the combined therapy of ICIs and PARPi in solid tumors from a bibliometric perspective. Methods: Publications concerning the combination of ICIs and PARPi in solid tumors during 2008–2022 were extracted from the WOSCC database. VOSviewer and R-bibliometrix were applied to conduct bibliometrics. Results: In total, 1113 articles were finally included. The USA was the most dominant country, and University of Texas MD Anderson Cancer Center was the most fruitful institute. Andreas Schneeweiss ranked first concerning the amount of publications in this research domain, and Timothy Yap had the most citations on this theme. The analysis of keyword co-occurrence indicated that research frontiers were shifted from the biological mechanisms of cell death to the combined strategy of ICIs and PARPi in clinical trials. Conclusions: Our study comprehensively examined the publications on the combination of ICIs and PARPi in solid tumors from a bibliometric perspective. The research on this topic is in its rapid growth stage, and the USA is possessing an absolutely leading position in this field by its scientific accumulations and productivity. Moreover, the research frontiers have shifted from the mechanisms of ICIs and PARPi to their combined treatment in clinical application. In summary, our results demonstrated a comprehensive overview of the knowledge atlas and a valuable reference for the future investigations in this field. |
| first_indexed | 2024-03-08T06:55:13Z |
| format | Article |
| id | doaj.art-ab3e1b90c9c44ed5ab096d49784cb26e |
| institution | Directory Open Access Journal |
| issn | 2405-8440 |
| language | English |
| last_indexed | 2024-03-08T06:55:13Z |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj.art-ab3e1b90c9c44ed5ab096d49784cb26e2024-02-03T06:37:32ZengElsevierHeliyon2405-84402024-01-01102e24452Bibliometric analysis of research trends on the combination of immune checkpoint inhibitors and PARP inhibitors in solid tumorsYaqian Tan0Qi Song1Department of Pharmacy, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, ChinaDepartment of Pharmacy, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China; Corresponding author.Introduction: Immune checkpoint inhibitors (ICIs) has made significant achievements in the therapeutics of various tumor types, and recently growing evidence from preclinical studies and clinical trials has indicated that poly-ADP-ribose polymerase inhibitors (PARPi) are exhibiting encouraging synergism with ICIs. The aim of our current study is to explore the development pattern of literature related to the combined therapy of ICIs and PARPi in solid tumors from a bibliometric perspective. Methods: Publications concerning the combination of ICIs and PARPi in solid tumors during 2008–2022 were extracted from the WOSCC database. VOSviewer and R-bibliometrix were applied to conduct bibliometrics. Results: In total, 1113 articles were finally included. The USA was the most dominant country, and University of Texas MD Anderson Cancer Center was the most fruitful institute. Andreas Schneeweiss ranked first concerning the amount of publications in this research domain, and Timothy Yap had the most citations on this theme. The analysis of keyword co-occurrence indicated that research frontiers were shifted from the biological mechanisms of cell death to the combined strategy of ICIs and PARPi in clinical trials. Conclusions: Our study comprehensively examined the publications on the combination of ICIs and PARPi in solid tumors from a bibliometric perspective. The research on this topic is in its rapid growth stage, and the USA is possessing an absolutely leading position in this field by its scientific accumulations and productivity. Moreover, the research frontiers have shifted from the mechanisms of ICIs and PARPi to their combined treatment in clinical application. In summary, our results demonstrated a comprehensive overview of the knowledge atlas and a valuable reference for the future investigations in this field.http://www.sciencedirect.com/science/article/pii/S2405844024004833PARP inhibitorsImmunotherapyImmune checkpoint inhibitorsCombination therapySolid tumorsBibliometric analysis |
| spellingShingle | Yaqian Tan Qi Song Bibliometric analysis of research trends on the combination of immune checkpoint inhibitors and PARP inhibitors in solid tumors Heliyon PARP inhibitors Immunotherapy Immune checkpoint inhibitors Combination therapy Solid tumors Bibliometric analysis |
| title | Bibliometric analysis of research trends on the combination of immune checkpoint inhibitors and PARP inhibitors in solid tumors |
| title_full | Bibliometric analysis of research trends on the combination of immune checkpoint inhibitors and PARP inhibitors in solid tumors |
| title_fullStr | Bibliometric analysis of research trends on the combination of immune checkpoint inhibitors and PARP inhibitors in solid tumors |
| title_full_unstemmed | Bibliometric analysis of research trends on the combination of immune checkpoint inhibitors and PARP inhibitors in solid tumors |
| title_short | Bibliometric analysis of research trends on the combination of immune checkpoint inhibitors and PARP inhibitors in solid tumors |
| title_sort | bibliometric analysis of research trends on the combination of immune checkpoint inhibitors and parp inhibitors in solid tumors |
| topic | PARP inhibitors Immunotherapy Immune checkpoint inhibitors Combination therapy Solid tumors Bibliometric analysis |
| url | http://www.sciencedirect.com/science/article/pii/S2405844024004833 |
| work_keys_str_mv | AT yaqiantan bibliometricanalysisofresearchtrendsonthecombinationofimmunecheckpointinhibitorsandparpinhibitorsinsolidtumors AT qisong bibliometricanalysisofresearchtrendsonthecombinationofimmunecheckpointinhibitorsandparpinhibitorsinsolidtumors |